Press Announcements > FDA requests removal of Opana ER for risks related to abuse

Press Announcements > FDA requests removal of Opana ER for risks related to abuse

FDA requests removal of Opana ER for risks related to abuse

06/08/2017 04:15 PM EDT

Today, the U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks. This is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse.